Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 11
Submit an article Journal homepage
127
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation

Jinyi ZhouJiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Key laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China
,
Qi QuJiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Key laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China
,
Suning ChenJiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Key laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China
,
Yang XuJiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Key laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China
,
Hongjie ShenJiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Key laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China
,
Jiannong CenJiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Key laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR China
&
Depei WuJiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Key laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215006, PR ChinaCorrespondence[email protected]
 show all
Pages 3207-3209 | Received 25 Aug 2014, Accepted 22 Feb 2015, Published online: 26 Aug 2015

References

  • Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340: 1330–1340.
  • Savona MR. Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia. J Community Support Oncol 2014;12:171–178.
  • Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63:789–799.
  • Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850–858.
  • Itonaga H, Tsushima H, Hata T, et al. Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. Int J Hematol 2012;95:209–213.
  • Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013;121:489–498.
  • Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 2013;122:1634–1648.
  • Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018–1029.
  • Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104: 3739–3745.
  • Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111: 4022–4028.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.